Press Releases

Press Releases

Samsung Biologics partners with LegoChem Biosciences for ADC development and manufacturing

Samsung Biologics partners with LegoChem Biosciences for ADC development and manufacturing

· Samsung Biologics to develop and manufacture antibody for ADC candidate

· Latest deal comes as Samsung Biologics is on track to complete construction of an ADC facility this year

 

Incheon, S. Korea, February 7, 2024 – Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced it has signed a partnership agreement with LegoChem Biosciences (KOSDAQ: 141080), a biotech company pioneering the research and development of antibody-drug conjugate (ADC) programs.

 

Under the terms of the deal, Samsung Biologics will provide antibody development and drug substance manufacturing services as a part of LegoChem Biosciences’ ADC program designed to treat solid tumors. LegoChem Biosciences aims to submit an Investigational New Drug application to the U.S. FDA in the first half of 2025, with non-clinical data showing promising efficacy results.

 

The company is also on track to adding ADC to its pipeline, with the construction of a standalone, dedicated ADC facility expected to be operational within 2024.

 

“Collaboration between Samsung Biologics and LegoChem Biosciences will enable us to deliver on our common goal to develop and manufacture efficient and safe therapeutics for patients,” said John Rim, CEO and President of Samsung Biologics. “We look forward to working with LegoChem Biosciences to support their pipeline of innovative ADC candidates and secure new opportunities in the fast-growing ADC field.”

 

“LegoChem Biosciences had previously supplied antibodies for ADC through only overseas companies, but we expect that we will be able to secure a stable domestic supply chain through this contract,” said Yong-Zu Kim, CEO and President of LegoChem Biosciences.

 

Samsung Biologics will offer comprehensive services for ADC development and manufacturing, building on its expertise and capacity in antibody engineering, process development, and large-scale manufacturing of antibodies. The company has also been making active investments through the Samsung Life Science Fund in biotech companies pioneering ADC linker technologies and toolbox.


Samsung Biologics partners with LegoChem Biosciences for ADC development and manufacturing

· Samsung Biologics to develop and manufacture antibody for ADC candidate

· Latest deal comes as Samsung Biologics is on track to complete construction of an ADC facility this year

 

Incheon, S. Korea, February 7, 2024 – Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced it has signed a partnership agreement with LegoChem Biosciences (KOSDAQ: 141080), a biotech company pioneering the research and development of antibody-drug conjugate (ADC) programs.

 

Under the terms of the deal, Samsung Biologics will provide antibody development and drug substance manufacturing services as a part of LegoChem Biosciences’ ADC program designed to treat solid tumors. LegoChem Biosciences aims to submit an Investigational New Drug application to the U.S. FDA in the first half of 2025, with non-clinical data showing promising efficacy results.

 

The company is also on track to adding ADC to its pipeline, with the construction of a standalone, dedicated ADC facility expected to be operational within 2024.

 

“Collaboration between Samsung Biologics and LegoChem Biosciences will enable us to deliver on our common goal to develop and manufacture efficient and safe therapeutics for patients,” said John Rim, CEO and President of Samsung Biologics. “We look forward to working with LegoChem Biosciences to support their pipeline of innovative ADC candidates and secure new opportunities in the fast-growing ADC field.”

 

“LegoChem Biosciences had previously supplied antibodies for ADC through only overseas companies, but we expect that we will be able to secure a stable domestic supply chain through this contract,” said Yong-Zu Kim, CEO and President of LegoChem Biosciences.

 

Samsung Biologics will offer comprehensive services for ADC development and manufacturing, building on its expertise and capacity in antibody engineering, process development, and large-scale manufacturing of antibodies. The company has also been making active investments through the Samsung Life Science Fund in biotech companies pioneering ADC linker technologies and toolbox.


SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION